Abbott reports quarterly sales declines, but boosts full-year profit outlook
startribune.com
news
2022-10-19 16:51:43

Despite sales declines, Abbott Laboratories topped Wall Street expectations and raised its full-year guidance on profits for the second time this year.

The medical company on Wednesday delivered earnings per share of $1.15, topping analysts' forecast of $0.94.

Chicago-based Abbott saw sales drop 4.7% to $10.4 billion for its third quarter, which ended Sept. 30.

Abbott's stock was down more than 7% in midday trading on Wednesday.

The company attributed its revenue decline to a softening in its COVID-19 at-home test kits compared to a year ago and the fallout from the closure of a baby formula plant in Michigan after the U.
